Viela Bio (NASDAQ:VIE) is set to release its earnings data after the market closes on Monday, March 1st. Analysts expect Viela Bio to post earnings of ($0.72) per share for the quarter.
Shares of Viela Bio stock traded up $0.08 during trading hours on Tuesday, reaching $52.98. The company’s stock had a trading volume of 33,323 shares, compared to its average volume of 1,127,674. The stock has a market cap of $2.91 billion, a P/E ratio of -7.57 and a beta of 0.43. The company’s 50 day simple moving average is $43.39 and its 200 day simple moving average is $37.97. Viela Bio has a one year low of $25.02 and a one year high of $70.66.
VIE has been the topic of several analyst reports. HC Wainwright downgraded shares of Viela Bio from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $52.00 to $53.00 in a research report on Tuesday, February 2nd. Guggenheim lowered shares of Viela Bio from a “buy” rating to a “neutral” rating in a research report on Monday, February 8th. Finally, Wedbush lowered shares of Viela Bio from an “outperform” rating to a “neutral” rating and set a $43.00 price target on the stock. in a report on Monday, February 8th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $54.50.
Viela Bio, Inc, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases.
Recommended Story: Net Asset Value
Receive News & Ratings for Viela Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viela Bio and related companies with MarketBeat.com's FREE daily email newsletter.